Literature DB >> 31288156

Differences between metabolically healthy and unhealthy obesity in PAI-1 level: Fibrinolysis, body size phenotypes and metabolism.

Lourdes Basurto1, Lucero Sánchez2, Alma Díaz2, Magdalena Valle2, Ariadna Robledo3, Carlos Martínez-Murillo4.   

Abstract

BACKGROUND: Different studies have recognized the existence of subtypes of obesity and normal weight, in which it is reported that not all patients show the same cardiometabolic risk, called "metabolically healthy" and "metabolically unhealthy". In several reviews, differences in the inflammatory profile have been studied, but there is not information on the relationship of body size phenotypes with thrombosis risk.
OBJECTIVE: Determine the association between body size phenotypes and fibrinolytic activity by measuring the concentration of plasminogen activator inhibitor-1 (PAI-1).
METHODS: A cross-sectional study was conducted in women aged 40 to 65 years. Anthropometric measurements and biochemical determinations were performed on all participants. The fibrinolytic activity was determined by measuring PAI-1 by ELISA. Karelis criteria were used to define metabolic status. Four groups were formed: Metabolically healthy normal weight (MHNW), Metabolically unhealthy normal weight (MUNW), Metabolically healthy obese (MHO) and Metabolically unhealthy obese (MUO).
RESULTS: 230 women were included in our study with a mean age 52.3 ± 5.9 years. The concentration of PAI-1 showed a significant difference between the groups MHNW, MUNW, MHO, MUO [2.3 (0.08, 13.6), 12.7, (0.08, 33.1), 23.4 (2.6, 28.8) and 22.8 (2.0, 46.7) ng/mL, respectively, p = 0.006]. Multiple regression analysis identified that BMI and HOMA-IR were independent factors influencing PAI-1 levels.
CONCLUSION: This study is the first one that recognizes differences in the fibrinolytic activity between body size phenotypes. The groups with the lowest fibrinolytic activity were MUO and MHO, however, MUNW also present alterations of fibrinolysis, thus suggesting a prothrombotic state.
Copyright © 2019 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Fibrinolysis; Obesity; Plasminogen activator inhibitor-1; Thrombosis

Year:  2019        PMID: 31288156     DOI: 10.1016/j.thromres.2019.06.013

Source DB:  PubMed          Journal:  Thromb Res        ISSN: 0049-3848            Impact factor:   3.944


  4 in total

1.  The Interaction Between Dietary Total Antioxidant Capacity and MC4R Gene and HOMA-IR in Metabolically Healthy and Unhealthy Overweight and Obese Women.

Authors:  Maryam ElhamKia; Leila Setayesh; Habib Yarizadeh; Sara Pooyan; Zahra Veisy; Vajihe Aghamohammadi; Krista Casazza; Khadijeh Mirzaei
Journal:  Nutr Metab Insights       Date:  2022-06-16

2.  Analysis and identification of novel biomarkers involved in neuroblastoma via integrated bioinformatics.

Authors:  Bo Chen; Peng Ding; Zhongyan Hua; Xiuni Qin; Zhijie Li
Journal:  Invest New Drugs       Date:  2020-08-08       Impact factor: 3.850

Review 3.  Melanoma Progression under Obesity: Focus on Adipokines.

Authors:  Joanna Olszańska; Katarzyna Pietraszek-Gremplewicz; Dorota Nowak
Journal:  Cancers (Basel)       Date:  2021-05-10       Impact factor: 6.639

4.  Association of Metabolically Healthy and Unhealthy Obesity Phenotype with Markers Related to Obesity, Diabetes among Young, Healthy Adult Men. Analysis of MAGNETIC Study.

Authors:  Mateusz Lejawa; Kamila Osadnik; Zenon Czuba; Tadeusz Osadnik; Natalia Pawlas
Journal:  Life (Basel)       Date:  2021-12-07
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.